Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses
<h3>Background</h3><p dir="ltr">Despite significant improvements in both treatment and prevention strategies, as well as multiple commissioned reviews, there remains uncertainty regarding the survival benefit of repurposed drugs such as colchicine in patients with Coronav...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , |
| Published: |
2023
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513529353076736 |
|---|---|
| author | Mohammed I. Danjuma (13569767) |
| author2 | Rana Sayed (17844398) Maryam Aboughalia (17844401) Aseel Hassona (17844404) Basant Selim Elsayed (17844407) Mohamed Elshafei (9376832) Abdelnaser Elzouki (13192181) |
| author2_role | author author author author author author |
| author_facet | Mohammed I. Danjuma (13569767) Rana Sayed (17844398) Maryam Aboughalia (17844401) Aseel Hassona (17844404) Basant Selim Elsayed (17844407) Mohamed Elshafei (9376832) Abdelnaser Elzouki (13192181) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohammed I. Danjuma (13569767) Rana Sayed (17844398) Maryam Aboughalia (17844401) Aseel Hassona (17844404) Basant Selim Elsayed (17844407) Mohamed Elshafei (9376832) Abdelnaser Elzouki (13192181) |
| dc.date.none.fl_str_mv | 2023-09-16T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.heliyon.2023.e20155 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Does_colchicine_reduce_mortality_in_patients_with_COVID-19_clinical_syndrome_An_umbrella_review_of_published_meta-analyses/25059986 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Pharmacology and pharmaceutical sciences COVID-19 Colchicine Meta-analysis Mortality Umbrella |
| dc.title.none.fl_str_mv | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background</h3><p dir="ltr">Despite significant improvements in both treatment and prevention strategies, as well as multiple commissioned reviews, there remains uncertainty regarding the survival benefit of repurposed drugs such as colchicine in patients with Coronavirus Disease 2019 (COVID-19) clinical syndrome.</p><h3>Methods</h3><p dir="ltr">In this umbrella review, we carried out a comprehensive search of PubMed, EMBASE, Cochrane Database of Systematic Reviews, Science Citation Index, and the Database of Abstracts of Reviews of Effectiveness between January 1, 2020 and January 31, 2023 for systematic reviews and meta-analyses evaluating the mortality-reducing benefits of colchicine in patients with COVID-19. This was to ascertain the exact relationship between colchicine exposure and mortality outcomes in these cohorts of patients. We utilized A Measurement Tool to Assess systematic Reviews-2 (AMSTAR-2) to conduct an exhaustive methodological quality and risk of bias assessment of the included reviews.</p><h3>Results</h3><p dir="ltr">We included eighteen meta-analyses (n = 199,932 participants) in this umbrella review. Colchicine exposure was associated with an overall reduction of about 32% in the risk of mortality (odds ratio 0.68, confidence interval [CI] 0.58–0.78; I2 = 94%, p = 0.001). Further examination of pooled estimates of mortality outcomes by the quality effects model (corrected for the methodological quality and risk of bias of the constituent reviews) reported similar point estimates (OR 0.73; CI 0.59 to 0.91; I2 = 94%).</p><h3>Conclusion</h3><p dir="ltr">In a pooled umbrella evaluation of published meta-analyses of COVID-19 patient cohorts, exposure to colchicine was associated with a reduction in overall mortality. Although it remains uncertain if this effect could potentially be attenuated or augmented by COVID-19 vaccination.</p><p><br></p><h2>Other Information</h2><p dir="ltr">Published in: Heliyon<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.heliyon.2023.e20155" target="_blank">https://dx.doi.org/10.1016/j.heliyon.2023.e20155</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_14d8c91d984a961b7920f058078b2aad |
| identifier_str_mv | 10.1016/j.heliyon.2023.e20155 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25059986 |
| publishDate | 2023 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analysesMohammed I. Danjuma (13569767)Rana Sayed (17844398)Maryam Aboughalia (17844401)Aseel Hassona (17844404)Basant Selim Elsayed (17844407)Mohamed Elshafei (9376832)Abdelnaser Elzouki (13192181)Biomedical and clinical sciencesPharmacology and pharmaceutical sciencesCOVID-19ColchicineMeta-analysisMortalityUmbrella<h3>Background</h3><p dir="ltr">Despite significant improvements in both treatment and prevention strategies, as well as multiple commissioned reviews, there remains uncertainty regarding the survival benefit of repurposed drugs such as colchicine in patients with Coronavirus Disease 2019 (COVID-19) clinical syndrome.</p><h3>Methods</h3><p dir="ltr">In this umbrella review, we carried out a comprehensive search of PubMed, EMBASE, Cochrane Database of Systematic Reviews, Science Citation Index, and the Database of Abstracts of Reviews of Effectiveness between January 1, 2020 and January 31, 2023 for systematic reviews and meta-analyses evaluating the mortality-reducing benefits of colchicine in patients with COVID-19. This was to ascertain the exact relationship between colchicine exposure and mortality outcomes in these cohorts of patients. We utilized A Measurement Tool to Assess systematic Reviews-2 (AMSTAR-2) to conduct an exhaustive methodological quality and risk of bias assessment of the included reviews.</p><h3>Results</h3><p dir="ltr">We included eighteen meta-analyses (n = 199,932 participants) in this umbrella review. Colchicine exposure was associated with an overall reduction of about 32% in the risk of mortality (odds ratio 0.68, confidence interval [CI] 0.58–0.78; I2 = 94%, p = 0.001). Further examination of pooled estimates of mortality outcomes by the quality effects model (corrected for the methodological quality and risk of bias of the constituent reviews) reported similar point estimates (OR 0.73; CI 0.59 to 0.91; I2 = 94%).</p><h3>Conclusion</h3><p dir="ltr">In a pooled umbrella evaluation of published meta-analyses of COVID-19 patient cohorts, exposure to colchicine was associated with a reduction in overall mortality. Although it remains uncertain if this effect could potentially be attenuated or augmented by COVID-19 vaccination.</p><p><br></p><h2>Other Information</h2><p dir="ltr">Published in: Heliyon<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.heliyon.2023.e20155" target="_blank">https://dx.doi.org/10.1016/j.heliyon.2023.e20155</a></p>2023-09-16T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.heliyon.2023.e20155https://figshare.com/articles/journal_contribution/Does_colchicine_reduce_mortality_in_patients_with_COVID-19_clinical_syndrome_An_umbrella_review_of_published_meta-analyses/25059986CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/250599862023-09-16T03:00:00Z |
| spellingShingle | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses Mohammed I. Danjuma (13569767) Biomedical and clinical sciences Pharmacology and pharmaceutical sciences COVID-19 Colchicine Meta-analysis Mortality Umbrella |
| status_str | publishedVersion |
| title | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| title_full | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| title_fullStr | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| title_full_unstemmed | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| title_short | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| title_sort | Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses |
| topic | Biomedical and clinical sciences Pharmacology and pharmaceutical sciences COVID-19 Colchicine Meta-analysis Mortality Umbrella |